Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Patients with nonmuscle-invasive bladder cancer who received intravesical chemotherapy after transurethral resection of bladder tumor had a significantly lower 30-day complication rate compared with those who did not receive intravesical chemotherapy.
Patients who received BCG induction within 3 weeks or 3 weeks or more after surgery for nonmuscle-invasive bladder cancer did not differ in their rates of BCG intolerance and recurrence- and progression-free survival, a study found.
As current guidelines only include a weak recommendation to offer perioperative chemotherapy to patients with muscle-invasive upper tract urothelial carcinoma, a new meta-analysis including evidence up to February 2020 provides potentially useful information.
The 2020 update highlights the importance of accurate diagnosis of upper tract urothelial carcinoma, risk stratification, close follow-up of patients receiving kidney-sparing management, and other key aspects of care.